Domine Gomez, Manuel manuel.domine@uam.es
Actividades
- Artículos 38
- Libros 1
- Capítulos de libro 0
- Congresos 0
- Documentos de trabajo 0
- Informes técnicos 0
- Proyectos de investigación 0
- Tesis dirigidas 0
- Patentes o licencias de software 0
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
- Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S, ETOP 10-16 BOOSTER Collaborators
Annals Of Oncology (p. 181-192) - 1/2/2022
10.1016/j.annonc.2021.11.010 Ver en origen
- ISSN 09237534
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
- Arriola, E
- Gonzalez-Cao, M
- Domine, M
- De Castro, J
- Cobo, M
- Bernabe, R
- Navarro, A
- Sullivan, I
- Trigo, JM
- Mosquera, J
- Crama, L
- Isla, D
Oncology And Therapy (p. 167-184) - 1/6/2022
10.1007/s40487-021-00182-0 Ver en origen
- ISSN 23661089
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
- Herbst RS
- Wu YL
- John T
- Grohe C
- Majem M
- Wang J
- Kato T
- Goldman JW
- Laktionov K
- Kim SW
- Yu CJ
- Vu HV
- Lu S
- Lee KY
- Mukhametshina G
- Akewanlop C
- De Marinis F
- Bonanno L
- Domine M
- Shepherd FA
- Urban D
- Huang X
- Bolanos A
- Stachowiak M
- Tsuboi M
Journal Of Clinical Oncology (p. 1830-1840) - 1/4/2023
10.1200/jco.22.02186 Ver en origen
- ISSN 0732183X
Anatomopathologic, clinical and therapeutic considerations on malignant tumors of the parotid. Our experience
- Arias de la Vega F
- Albert Solis J
- Perez Casas A
- Martinez Lopez E
- Domine Gomez M
- Melchor Iniguez M
Oncologia (p. 145-151) - 1/1/1988
- ISSN 03784835
- iMarina
Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting
- Dómine Gómez M
- Díaz Fernández N
- Cantos Sánchez de Ibargüen B
- Zugazabeitia Olabarría L
- Martínez Lozano J
- Poza de Celis R
- Trujillo Vílchez R
- Peláez Fernández I
- Capdevila Castillón J
- Traseira Lugilde S
- Esteban González E
Advances In Therapy (p. 136-147) - 1/1/2017
10.1007/s12325-016-0435-1 Ver en origen
- ISSN 0741238X
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial
- Provencio M
- Ortega AL
- Coves-Sarto J
- Calvo V
- Marsé-Fabregat R
- Dómine M
- Guirado M
- Carcereny E
- Fernández N
- Álvarez R
- Blanco R
- León-Mateos L
- Sánchez-Torres JM
- Sullivan IG
- Cobo M
- Sánchez-Hernández A
- Massuti B
- Sierra-Rodero B
- Mártinez-Toledo C
- Serna-Blasco R
- Romero A
- Cruz-Bermúdez A
Jama Oncology (p. 344-353) - 16/3/2023
10.1001/jamaoncol.2022.5959 Ver en origen
- ISSN 23742445
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
- Laza-Briviesca, Raquel
- Cruz-Bermudez, Alberto
- Nadal, Ernest
- Insa, Amelia
- Garcia-Campelo, Maria del Rosario
- Huidobro, Gerardo
- Domine, Manuel
- Majem, Margarita
- Rodriguez-Abreu, Delvys
- Martinez-Marti, Alex
- De Castro Carpeno, Javier
- Cobo, Manuel
- Lopez Vivanco, Guillermo
- Del Barco, Edel
- Bernabe Caro, Reyes
- Vinolas, Nuria
- Barneto Aranda, Isidoro
- Viteri, Santiago
- Massuti, Bartomeu
- Casarrubios, Marta
- Sierra-Rodero, Belen
- Tarin, Carlos
- Garcia-Grande, Aranzazu
- Haymaker, Cara
- Wistuba, Ignacio I.
- Romero, Atocha
- Franco, Fernando
- Provencio, Mariano;
Clinical And Translational Medicine - 1/7/2021
10.1002/ctm2.491 Ver en origen
- ISSN 20011326
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
- Aix SP
- Ciuleanu TE
- Navarro A
- Cousin S
- Bonanno L
- Smit EF
- Chiappori A
- Olmedo ME
- Horvath I
- Grohé C
- Farago AF
- López-Vilariño JA
- Cullell-Young M
- Nieto A
- Vasco N
- Gómez J
- Kahatt C
- Zeaiter A
- Carcereny E
- Roubec J
- Syrigos K
- Lo G
- Barneto I
- Pope A
- Sánchez A
- Kattan J
- Zarogoulidis K
- Waller CF
- Bischoff H
- Juan-Vidal O
- Reinmuth N
- Dómine M
- Paz-Ares L
Lancet Respiratory Medicine (p. 74-86) - 1/1/2023
10.1016/s2213-2600(22)00309-5 Ver en origen
- ISSN 22132600
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
- Provencio M
- Cobo M
- Rodriguez-Abreu D
- Calvo V
- Carcereny E
- Cantero A
- Bernabé R
- Benitez G
- Castro RL
- Massutí B
- del Barco E
- García Campelo R
- Guirado M
- Camps C
- Ortega AL
- González Larriba JL
- Sánchez A
- Casal J
- Sala MA
- Juan-Vidal O
- Bosch-Barrera J
- Oramas J
- Dómine M
- Trigo JM
- Blanco R
- Calzas J
- Morilla I
- Padilla A
- Pimentao J
- Sousa PA
- Torrente M
Bmc Cancer - 1/12/2022
10.1186/s12885-022-09830-8 Ver en origen
- ISSN 14712407
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüro?lu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Ka?arnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN investigators
Lancet Oncology (p. 51-65) - 1/1/2021
10.1016/s1470-2045(20)30539-8 Ver en origen
- ISSN 14702045
Este/a investigador/a no tiene capítulos de libro.
Este/a investigador/a no tiene congresos.
Este/a investigador/a no tiene documentos de trabajo.
Este/a investigador/a no tiene informes técnicos.
Este/a investigador/a no tiene proyectos de investigación.
Este/a investigador/a no tiene tesis dirigidas.
Este/a investigador/a no tiene patentes o licencias de software.
Perfiles de investigador/a
-
ORCID
-
Scopus Author ID
-
Dialnet id